Acute heart failure data for Corthera's relaxin data "probably too good to be true"
This article was originally published in Scrip
Executive Summary
The US biopharmaceutical company Corthera (formerly BAS Medical) is set to take its lead product, a recombinant version of the human hormone relaxin, into Phase III by the end of this year on the back of highly promising Phase IIb data in acute heart failure (AHF).